Maxillofacial Plastic and Reconstructive Surgery

Korean Association of Maxillofacial Plastic and Reconstructive Surgeons (대한악안면성형재건외과학회)
권호 표지

GROWTH INHIBITION OF ORAL SQUAMOUS CELL CARCINORMA CELL LINE INDUCED BY COX INHIBITOR

COX 억제제에 의해 유도되는 구강편평세포암종 세포주의 성장 억제 효과

  • Park, Gwang-Jin (Department of Oral & Maxillofacial Surgery, College of Dentistry, Dankook University) ;
  • Han, Se-Jin (Department of Oral & Maxillofacial Surgery, College of Dentistry, Dankook University) ;
  • Lee, Jae-Hoon (Department of Oral & Maxillofacial Surgery, College of Dentistry, Dankook University)
  • 박광진 (단국대학교 치과대학 구강악안면외과학교실) ;
  • 한세진 (단국대학교 치과대학 구강악안면외과학교실) ;
  • 이재훈 (단국대학교 치과대학 구강악안면외과학교실)
  • Published : 2008.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

The objectives of this study was to explore the growth pattern of the oral squamous cell carcinoma when overexpressed COX was inhibited, explore the pathway that COX inhibitors suppressed the proliferation of cancer cells, and then hereafter investigate the potential of COX as chemopreventive target for oral squamous cell carcinoma. For confirming the COX-dependent effect and mechanisms on growth of the oral cancer cells, we treated the nonselective NSAID, Mefenamic acid and COX-2 selective inhibitor, Celecoxib in HN4 cell line. And then the cell line was evaluated with MTT assay and growth curve, the production of PGE2, total RNA extraction and RT-PCR analysis, and TEM The results were obtained as follows: 1. After administration of medication, in the result of MTT assay, Celecoxib inoculated group inhibit the cell growth rather than Mefenamic acid inoculated group. 2. The growth curve of cell line showed as time passes by there was a dramatic cell growth in the control group, and gradual growth inhibition was found in medication inoculated group and, in Celecoxib inoculated group there was more inhibition of cell growth. 3. After the administration of medication, Celecoxib tend to inhibit the synthesis of PGE2 more than Mefenamic acid. Mefenamic acid inhibit the synthesis of PGE2 more as the concentration gets high, but Celecoxib inhibited the synthesis of PGE2 even in low concentration. 4. After the administration of medication, the revelation of COX mRNA in cell line, there was a 50% decrease in COX-1, 60% decrease in COX-2 as in $50{\mu}M$ Mefenamic acid, and in Celecoxib $50{\mu}M$ there was not much difference in COX-1 and 90% decrease in COX-2 was found. 5. HN4 cell line showed broken nucleus and tangled cytoskeleton bundles in cytoplasm which meant apoptotic features after the treatment of Celecoxib in TEM view. Depending on the above results, we estimate that the inhibition of the expression of COX-2 cause the growth suppression of the oral squamous cell carcinoma, and it get achieved through pathway of reduced PGE2 production and increased apoptosis. In addition to, because COX-2 selective inhibitor specifically act to COX-2, it is considered that COX-2 selective inhibitor has the adequate potential as chemopreventive agent for oral squamous cell carcinoma.

Keywords

References

  1. Parkin DM : Global cancer statistics in the year 2000. Lancet Oncol 2 : 533, 2001 https://doi.org/10.1016/S1470-2045(01)00486-7
  2. Mork J : Forty years of monitoring head and neck cancer in Norway?no good news. Anticancer Res 18 : 3705, 1998
  3. Forastiere A, Koch W, Trotti A et al : Head and neck cancer. N Engl J Med 345 : 1890, 2001 https://doi.org/10.1056/NEJMra001375
  4. Lippman SM, Hong WK : Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 17 : 691, 1989 https://doi.org/10.1016/0360-3016(89)90126-0
  5. Thun MJ, Henley SJ, Patrono C : Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst (Bethesda) 94 : 252, 2002 https://doi.org/10.1093/jnci/94.4.252
  6. DuBois RN, Abramson SB, Crofford L et al : Cyclooxygenase in biology and disease. FASEB J 12 : 1063, 1998 https://doi.org/10.1096/fasebj.12.12.1063
  7. Reed DW, Bradshaw WS, Xie W et al : In vivo and in vitro expression of a non-mammalian cyclooxygenase-1. Prostaglandins 52 : 269, 1996 https://doi.org/10.1016/S0090-6980(96)00089-5
  8. Williams CW, DuBois RN : Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 270 : G393, 1996
  9. Nathans D, Lau LF, Christy B et al : Genomic response to growth factors. Cold Spring Harbor Symp Quant Biol 53 : 893, 1998
  10. Herschman HR : Primary response genes induced by growth factors and tumor promoters. Ann Rev Biochem 60 : 281, 1991 https://doi.org/10.1146/annurev.bi.60.070191.001433
  11. Masferrer JL, Zweifel BS, Manning PT et al : Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91 : 3228, 1994 https://doi.org/10.1073/pnas.91.8.3228
  12. Simon LS : Actions and toxicity of nonsteroidal anti-inflammatory drugs. Curr Opin Rheum 8 : 169, 1996 https://doi.org/10.1097/00002281-199605000-00001
  13. Waddell WR, Loughry RW : Sulindac for polyposis of the colon. J Surg Oncol 24 : 83, 1983 https://doi.org/10.1002/jso.2930240119
  14. Waddell WR, Ganser GF, Cerise EJ et al : Sulindac for polyposis of the colon. Am J Surg 157 : 175, 1989 https://doi.org/10.1016/0002-9610(89)90442-X
  15. Smalley WE, DuBois RN : Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39 : 1, 1997 https://doi.org/10.1016/S1054-3589(08)60067-8
  16. Oshima M, Dinchuk JE, Kargman SL et al : Suppression of intestinal polyposis in Apc716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 : 803, 1996 https://doi.org/10.1016/S0092-8674(00)81988-1
  17. Kawamori T, Rao CV, Seibert K et al : Chemopreventive activity of Celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58 : 409, 1998
  18. Chan G, Boyle JO, Yang EK et al : Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59 : 991, 1999
  19. Brown JR, DuBois RN : COX-2: A molecular target for colorectal cancer prevention. J Clin Oncol 23 : 2840, 2005 https://doi.org/10.1200/JCO.2005.09.051
  20. Hanif R, Pittas A, Feng Y et al : Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52 : 237, 1996 https://doi.org/10.1016/0006-2952(96)00181-5
  21. Dannenberg AJ, Altorki NK, Boyle JO et al : Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer. Lancet Oncol 2 : 544, 2001 https://doi.org/10.1016/S1470-2045(01)00488-0
  22. Bright-Thomas RM, Hargest R : APC, beta-Catenin and hTCF-4: An unholy trinity in the genesis of colorectal cancer. Eur J Surg Oncol 29 : 107, 2003 https://doi.org/10.1053/ejso.2002.1331
  23. Dannenberg AJ, DuBois RN(eds) : COX-2: A New Target for Cancer Prevention and Treatment. New York, NY, Karger, 2003, p.52
  24. Scioscia KA, Snyderman CH, Rueger R et al : Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal anti-inflammatory drugs. Am J Otol 18 : 1, 1997 https://doi.org/10.1016/S0196-0709(97)90041-7
  25. Tsujii M, DuBois RN : Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 : 705, 1995
  26. Hong SH, Ondtey FG, Avis IM et al : Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J 14 : 1449, 2000
  27. Kelly DJ, Mestre JR, Subramaniak K et al : Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 18 : 795, 1997 https://doi.org/10.1093/carcin/18.4.795
  28. Eling TE, Thompson DC, Foureman GL et al : Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 30 : 1, 1990 https://doi.org/10.1146/annurev.pa.30.040190.000245
  29. Ziche M, Jones J, Gullino PM : Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 69 : 475, 1982
  30. Form DM, Auerbach R : PGE2 and angiogenesis. Proc Soc Exp Biol Med 172 : 214, 1983 https://doi.org/10.3181/00379727-172-41548
  31. Goodwin JS, Ceuppens J : Regulation of the immune response by prostaglandins. J Clin Immunol 3 : 295, 1983 https://doi.org/10.1007/BF00915791
  32. Lang S, Lauffer L, Clausen C et al : Impaired monocyte function in cancer patients: Restoration with a cyclooxygenase-2 inhibitor. FASEB J 17 : 286, 2003 https://doi.org/10.1096/fj.02-0417fje
  33. El Attar TM, Lin HS : Prostaglandin synthesis by squamous carcinoma cells of head and neck, and its inhibition by non-steroidal anti-inflammtory drugs. J Oral Pathol 16 : 483, 1987 https://doi.org/10.1111/j.1600-0714.1987.tb00677.x
  34. Jabbour H, Milne S, Williams A et al : Expression of COX-2 and PGE synthase and synthesis of PGE2 in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer 85 : 1023, 2001 https://doi.org/10.1054/bjoc.2001.2033
  35. Sonoshita M, Takaku K, Sasaki N et al : Acceleration of intestinal polyposis through prostaglandin receptor EP2 in APC (716) knockout mice. Nat Med 7 : 1048, 2001 https://doi.org/10.1038/nm0901-1048
  36. Yip-Schneider MT, Sweeney CJ, Jung SH et al : Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 298 : 976, 2001
  37. Holmgren L, O'Reilly MS, Folkman J : Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1 : 149, 1995 https://doi.org/10.1038/nm0295-149
  38. Boolbol SK, Dannenberg AJ, Chadburn A et al : Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56 : 2556, 1996
  39. Barnes CJ, Lee M : Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114 : 873, 1998 https://doi.org/10.1016/S0016-5085(98)70305-1
  40. Sheng H, Shao J, Morrow JD et al : Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58 : 362, 1998
  41. Cutler NS, Graves-Deal R, LaFleur BJ et al : Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res 63 : 1748, 2003
  42. Chan TA, Morin PJ, Vogelstein B et al : Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95 : 681, 1998 https://doi.org/10.1073/pnas.95.2.681
  43. Kundu N, Smyth MJ, Samsel L et al : Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat 76 : 57. 2002 https://doi.org/10.1023/A:1020224503335
  44. Reed JC : Fenretinide: the death of a tumor cell. J Natl Cancer Inst 91 : 1099, 1999 https://doi.org/10.1093/jnci/91.13.1099
  45. DuBois RN, Shao J, Tsujii M et al : G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 56 : 733, 1996
  46. Toyoshima T, Kamijo R, Takizawa K et al : Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br J Cancer 86 : 1150, 2002 https://doi.org/10.1038/sj.bjc.6600183
  47. Furuta Y, Hall ER, Sanduja S et al : Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res 48 : 3002, 1988
  48. Gilroy D, Saunders M, Wu K : COX-2 expression and cell cycle progression in human fibroblasts. Am J Physiol Cell Physiol 281 : C188, 2001 https://doi.org/10.1152/ajpcell.2001.281.1.C188
  49. Gilroy D, Saunders M, Sansores-Garcia L et al : Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts. FASEB J 15 : 288, 2001 https://doi.org/10.1096/fj.00-0573fje
  50. Moore RJ, Zweifel BS, Heuvelman DM et al : Enhanced antitumor activity co-administration of celecoxib and the chemotherapeutic agents cyclophosphamide and 5-fu. Proceedings of the American Association for Cancer Research: 1-5 April Cadmus Journal Services, Linthicum, MD USA Abstract 2600, 2000, p.409
  51. Kishi K, Petersen S, Petersen C et al : Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60 : 1326, 2000
  52. Harris RE, Alshafie GA, Abou-Issa H et al : Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60 : 2101, 2000